Keyword: NewLink Genetics
NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.
Despite a run of poor results in trials, IDO inhibition is still a worthy target in cancer immunotherapy, says NewLink CMO Eugene Kennedy.
Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics.
The studies are the latest dominoes to fall following the failure of Incyte’s rival IDO drug to move the needle in a pivotal trial.
The collaborators will jointly fund a phase 2 trial of the anti-PD-L1 drug-IDO pathway inhibitor combination in pancreatic cancer patients.
Roche is axing work on IDO med indoximod and handing back the rights to partner NewLink Genetics.
After its cancer vaccine platform bombed last year, NewLink has needed a win for its IDO inhibitor portfolio. So far, it hasn't quite hit the mark.
The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.
NewLink Genetics saw its shares plunge after it announced that a Phase III trial for its pancreatic cancer vaccine flopped.